Synthesis and biological activity of tyrosine protein kinase inhibitors
Pang, S.H.; Guo, Z.R.; Liang, X.T.
Yao Xue Xue Bao 32(7): 515-523
1997
ISSN/ISBN: 0513-4870 PMID: 11596277 Document Number: 474109
Four classes of 25 tyrosine protein kinase (TPK) inhibitors were designed and synthesized. Compounds 1 apprx 10 were tested to inhibit TPK of HL-60 leukemia cell using 32P-ATP method, and some of them exhibit evident inhibitory activities. Their structure-activity relationship is similar to that of TPK inhibitors reported in literatures. Compounds 11 apprx 25 were tested to inhibit TPK of normal rat spleen cell using ELISA method and their SAR is different from that using 32P-ATP method.
Document emailed within 1 workday
Related Documents
Bhatia, R.; Munthe, H.A.; Verfaillie, C.M. 1998: Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors Leukemia 12(11): 1708-1717Lu, H.; Sun, T.; Yao, L.; Zhang, Y. 2000: Role of protein tyrosine kinase in IL-1 beta induced activation of mitogen-activated protein kinase in fibroblast-like synoviocytes of rheumatoid arthritis Chinese Medical Journal 113(10): 872-876
Majumdar, A.P.; Goldenring, J.R. 1998: Localization and significance of pp55, a gastric mucosal membrane protein with tyrosine kinase activity American journal of physiology 274(5): G863-G870
Durocher, Y.; Chapdelaine, A.; Chevalier, S. 1989: Tyrosine protein kinase activity of human hyperplastic prostate and carcinoma cell lines PC3 and DU145 Cancer Research 49(17): 4818-4823
Bagadi, S.; Saikia, T.; Pany, A.; Das, B. 2011: Analysis of ABL Kinase Domain Mutations Conferring Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Cases from India Clinical Laboratory 57(7-8): 619-623
Chatzinikolaou, G.; Nikitovic, D.; Stathopoulos, E.N.; Velegrakis, G.A.; Karamanos, N.K.; Tzanakakis, G.N. 2007: Protein tyrosine kinase and estrogen receptor-dependent pathways regulate the synthesis and distribution of glycosaminoglycans/proteoglycans produced by two human colon cancer cell lines Anticancer Research 27(6b): 4101-4106
Haidar, S.; Meyers, A.; Bollacke, A.; Jose, J. 2015: Synthesis and biological evaluation of 2,6-di(furan-3-yl)anthracene-9, 10-dione as an inhibitor of human protein kinase CK2 Die Pharmazie 70(12): 772-776
Furspan, P.B.; Mayes, M.D.; Freedman, R.R. 2001: Effect of temperature and modulators of protein tyrosine kinase activity on the reactivity of isolated venules in secondary Raynaud's phenomenon Journal of Rheumatology 28(10): 2263-2268
Cartwright, C.A.; Mamajiwalla, S.; Skolnick, S.A.; Eckhart, W.; Burgess, D.R. 1993: Intestinal crypt cells contain higher levels of cytoskeletal-associated pp60c-src protein tyrosine kinase activity than do differentiated enterocytes Oncogene 8(4): 1033-1039
Li, P.M.; Fukazawa, H.; Mizuno, S.; Uehara, Y. 1993: Evaluation of protein kinase inhibitors in an assay system containing multiple protein kinase activities Anticancer Research 13(6a): 1957-1964
Mufson, R.A.; Szabo, J.; Eckert, D. 1992: Human IL-3 induction of c-jun in normal monocytes is independent of tyrosine kinase and involves protein kinase C Journal of Immunology 148(4): 1129-1135
Akagi, T.; Ono, H.; Shimotohno, K. 1996: Tyrosine kinase inhibitor herbimycin A reduces the stability of cyclin-dependent kinase Cdk6 protein in T-cells Oncogene 13(2): 399-405
Caliendo, G.; Fiorino, F.; Grieco, P.; Perissutti, E.; De Luca, S.; Giuliano, A.; Santelli, G.; Califano, D.; Severino, B.; Santagada, V. 1999: Synthesis and biological activity of pseudopeptides inhibitors of Ras farnesyl transferase containing unconventional amino acids Farmaco 54(11-12): 785-790
Wendtner, C.M.; Schmitt, B.; Gruss, H.J.; Druker, B.J.; Emmerich, B.; Goodwin, R.G.; Hallek, M. 1995: CD30 ligand signal transduction involves activation of a tyrosine kinase and of mitogen-activated protein kinase in a Hodgkin's lymphoma cell line Cancer Research 55(18): 4157-4161
Goldman, J. 2004: CML resistance to tyrosine kinase inhibitors: how is the laboratory to tell? Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology 10(3): 181-184
Junger, W.G.; Hoyt, D.B.; Hamreus, M.; Liu, F.C.; Herdon-Remelius, C.; Junger, W.; Altman, A. 1997: Hypertonic saline activates protein tyrosine kinases and mitogen-activated protein kinase p38 in T-cells Journal of Trauma 42(3): 437-43; Discussion 443-5
Przytulska, J.; Tupikowski, K.; Bednarek-Tupikowska, G. 2014: Thyroid dysfunction in patients treated with tyrosine kinase inhibitors Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 36(211): 42-44
Reid, T-Elinor.; Fortunak, J.M.; Wutoh, A.; Simon Wang, X. 2016: Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors Current Topics in Medicinal Chemistry 16(13): 1452-1462
Mahon, F.-X. 2019: When can tyrosine kinase inhibitors be discontinued in patients with chronic myeloid leukemia? Clinical Advances in Hematology and Oncology: H&o 17(2): 101-103
Wei, Z.Y.; Roerig, S.C. 1998: Spinal morphine/clonidine antinociceptive synergism is regulated by protein kinase C, but not protein kinase A activity Journal of Pharmacology and Experimental Therapeutics 287(3): 937-943